SOUTHLAKE, Texas--(BUSINESS WIRE)--OncoNano Medicine, Inc. today announced the appointment of Dr. Kartik Krishnan, MD, PhD to Chief Executive Officer (CEO) and member of the Board of Directors. Dr. Krishnan joined OncoNano as Chief Medical Officer in 2022 and ascended to the role of President and Head of Research and Development last year.

德克萨斯州南湖市——（商业新闻短讯）——OncoNano Medicine，Inc.今天宣布任命Kartik Krishnan博士为首席执行官（CEO）和董事会成员。Krishnan博士于2022年加入Onconnano担任首席医疗官，并于去年晋升为总裁兼研发主管。

He succeeds Martin Driscoll, who served as CEO since January 2021, and helped advance the company’s therapeutic pipeline into the clinic..

他接替了自2021年1月起担任首席执行官的马丁·德里斯科尔（MartinDriscoll），并帮助推动了公司的治疗渠道进入诊所。。

“Kartik is a highly experienced executive and passionate physician-scientist who has been an essential force for OncoNano’s success in the last two years,“ said Dr. Brett Giroir, Chairman of the Board of Directors of OncoNano. “We are confident as CEO he will champion not only the science, but OncoNano’s continued growth and development as a pioneer in innovative cancer therapies.”.

OncoNano董事会主席布雷特·吉罗伊尔（BrettGiroir）博士表示：“Kartik是一位经验丰富的执行官和充满激情的医生科学家，在过去两年中，他是OncoNano取得成功的重要力量。作为首席执行官，我们有信心他不仅会支持这项科学，而且会支持OncoNano作为创新癌症疗法先驱的持续增长和发展。”。

Dr. Krishnan has over two decades of experience dedicated to people suffering from cancer. Prior to joining OncoNano, he served as Chief Medical Officer of Arcus Biosciences, a publicly traded immuno-oncology company, for which he led a portfolio of biologics and small molecules in multiple phases of development.

克里希南博士在癌症患者身上有着20多年的经验。在加入OncoNano之前，他曾担任Arcus Biosciences的首席医疗官，Arcus Biosciences是一家上市的免疫肿瘤学公司，为此，他在多个开发阶段领导了一系列生物制剂和小分子产品。

Dr. Krishnan has excelled in both R&D and pharmacovigilance at multiple biotechnology and large pharmaceutical companies in roles of increasing responsibility. During his tenure at OncoNano, he has spearheaded the progression of ONM-501, a dual-activating STING agonist, into first in human studies and prioritized the next set of novel pipeline medicines..

Krishnan博士在多家生物技术和大型制药公司的研发和药物警戒方面表现出色，承担着越来越大的责任。在OncoNano任职期间，他率先将双重激活STING激动剂ONM-501的研究进展为人类研究中的第一个，并优先考虑了下一组新型管道药物。。

“I joined OncoNano almost two years ago on the promise of a technology that could change how cancer is treated and today am even more enthusiastic about its prospects,” said Dr. Krishnan. “Our goal is to accelerate development of OncoNano’s core technology platform and bring transformative medicines to patients.

克里希南博士说：“大约两年前，我加入了OncoNano，因为我承诺这项技术可以改变癌症的治疗方式，今天我对它的前景更加热情。”。“我们的目标是加速开发OncoNano的核心技术平台，并为患者带来变革性药物。

Thanks to Marty’s leadership we have a team focused on executing this mission, and I look forward to charting our progress.”.

感谢马蒂的领导，我们有一个专注于执行这项任务的团队，我期待着制定我们的进展。”。

With Dr. Krishnan’s appointment comes the promotion of Dr. Melissa Paoloni to Executive Vice President and Chief Operating Officer. Dr. Paoloni joined OncoNano in December of 2023 to lead both corporate and strategic development and will work alongside Dr. Krishnan to oversee the management team. Melissa brings long standing expertise in business development, alliance management and portfolio strategy across several organizations, most recently as Vice President of Corporate Development and External Alliances at Arcus Biosciences.

随着Krishnan博士的任命，Melissa Paoloni博士被提升为执行副总裁兼首席运营官。Paoloni博士于2023年12月加入Onconnano，领导公司和战略发展，并将与Krishnan博士一起监督管理团队。梅丽莎在多个组织的业务发展、联盟管理和投资组合战略方面拥有长期的专业知识，最近担任了Arcus Biosciences公司发展和外部联盟副总裁。

Her elevation will support OncoNano’s corporate planning, communications, partnering and stakeholder engagement..

她的提升将支持OncoNano的公司规划、沟通、合作和利益相关者参与。。

About OncoNano Medicine

关于OncoNano医学

OncoNano Medicine is developing a new class of cancer therapeutics that utilize principles of molecular cooperativity in their design to exploit pH to diagnose and treat solid tumors with high specificity. Our polymeric micelles are designed to efficiently deliver oncology payloads to the tumor microenvironment for an enhanced therapeutic index.

OncoNano Medicine正在开发一类新的癌症治疗药物，该药物在设计中利用分子协同原理来利用pH来诊断和治疗具有高特异性的实体瘤。我们的聚合物胶束旨在有效地将肿瘤学有效载荷传递到肿瘤微环境中，以增强治疗指数。

Our product candidates and interventions are designed to help patients across the continuum of cancer care and include solid tumor therapeutics, a platform of immuno-oncology therapeutics that activate and guide the body’s immune system to target cancer, and agents for real-time image guided surgery..

我们的候选产品和干预措施旨在帮助患者跨越癌症护理的整个过程，包括实体瘤治疗，激活和引导身体免疫系统靶向癌症的免疫肿瘤治疗平台，以及实时图像引导手术的药物。。

OncoNano’s ON-BOARD™ platform is generating a robust oncology pipeline to support novel therapeutic development for patients with high unmet medical need. ONM-501, OncoNano’s first therapeutic program is a next generation dual-activating STING (STimulator of INterferon Genes) agonist currently in phase 1 studies.

OncoNano的ON-BOARD™平台正在生成一个强大的肿瘤学管道，以支持针对高度未满足医疗需求的患者的新型治疗开发。ONM-501，Onconnano的第一个治疗计划是目前正在进行1期研究的下一代双重激活STING（干扰素基因刺激剂）激动剂。

ONM-412, the highly potent pro-inflammatory cytokine, interleukin-12 (IL-12), encapsulated in the ON-BOARD™ polymeric micelle system is currently advancing in preclinical development. Additionally, the ON-BOARD™ platform has been used for pegsitacianine, a novel fluorescent nanoprobe that is being studied as a real-time surgical imaging agent for use in multiple cancer surgeries and is advancing towards a pivotal clinical trial to aid in tumor detection of peritoneal carcinomatosis.

ONM-412是封装在ON-BOARD™聚合物胶束系统中的高效促炎细胞因子白细胞介素-12（IL-12），目前正在临床前开发中。此外，ON-BOARD™平台已被用于pegsitacianine，这是一种新型荧光纳米探针，正在研究作为实时外科成像剂用于多种癌症手术，并正在朝着关键的临床试验迈进，以帮助肿瘤检测腹膜癌病。

OncoNano is the top recipient of grants from CPRIT, which has supported the pegsitacianine and ONM-501 programs. Learn more about OncoNano’s platform and pipeline at www.OncoNano.com..

OncoNano是CPRIT赠款的最大接受者，CPRIT支持了pegsitacianine和ONM-501项目。有关OncoNano平台和管道的更多信息，请访问www.OncoNano.com。。